Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.
Analyst says MannKind’s Afrezza revenues can surpass debt, if investors can be patient for adoption.
Adamis Stock Can Reach $13 as Symjepi Deal Is Imminent
Analyst Jason Kolbert of Maxim believes that Interpace Diagnostics Group Inc (NASDAQ:IDXG) has quite the upper hand over the leading market ruler Veracyte …
Shares of MannKind Corporation (NASDAQ:MNKD) are up nearly 3% in Friday trading session, as the inhaled insulin drug maker gets a vote …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday’s trading session, following the news that CEO David Dodd is stepping …
Drug maker Omeros Corporation (NASDAQ:OMER) delivered solid results for its earnings report for the first quarter of the year 2017. In reaction, Maxim analyst Jason …
Maxim analyst Jason Kolbert slashes his price target on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to $5.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are rising almost 8% today on the heels of indicating it intends to file a new drug …
In a research released Friday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Sophiris Bio Inc (NASDAQ:SPHS), with a price target …